|
A Message from Monument Traders Alliance
Dear Reader,
Recently, Anthropic’s IPO prospectus leaked to the public.
Everyone’s buzzing over what’s inside its 261 pages.
But the most surprising thing is a critical fact almost nobody is talking about that’s not in the prospectus at all.
One that could help investors TRIPLE their money on the back of this record $2 trillion IPO in the years ahead.
Everyone knows Amazon and Google own big pieces of Anthropic.
But tech visionary Matt McCall has been tracking a much smaller partner. It got in early, back when most folks had never heard of Claude.
He calls it a “Second IPO.” And he just gave away its name and ticker in a free interview.
For the full story (including name and ticker) click here.
Yours in smart speculation,
Stephen Prior, Publisher
Monument Traders Alliance
The Real Reason Moderna Dropped 7% in a Single Day
On Thursday, Nov. 12, shares of Moderna fell about 7%. The stock closed at $231.35, down from $248.69 at the close on Wednesday, Nov. 11.
The drop came on the day the vaccine maker held its 2026 Analyst Day, a presentation where management lays out its plans for investors.
Why It Fell
The headline news sounded good. In its Nov. 12 press release, Moderna said it expects 2026 revenue growth of 15% to 25%, up from its original outlook of up to 10%.
The worry was 2027. Moderna said it expects about $4 billion in cash costs that year, and $4 billion to $4.5 billion a year through 2030, mostly for cancer treatments.
Cash costs are expenses minus stock-based pay and depreciation. Yahoo Finance tied the decline to that spending plan and noted that last November's Analyst Day had put 2027 cash costs at $3.5 billion to $3.9 billion.
The Bull View
Bulls point to the science and the sales trend. Moderna's third-quarter revenue rose 29% to $1.3 billion, and GAAP net income was $162 million, per its Nov. 6 earnings release.
In a Phase 3 melanoma trial, its personalized cancer vaccine intismeran, given with Merck's Keytruda, cut the risk of recurrence or death by 42%. The company also expects about $9 billion in liquidity at the end of 2026.
The Bear View
Bears say the good news is already priced in. Yahoo Finance, citing TIKR data, reported that Moderna traded at 44 times forward sales at the Nov. 11 close, against a five-year average of 8.2 times.
The same Nov. 12 article cited an analyst consensus revenue estimate of $3.68 billion for 2028, still below $4 billion in yearly cash costs. The cancer vaccine is also not yet approved, and any launch depends on regulators.
What Comes Next
Moderna said formal 2027 guidance is expected on its fourth-quarter 2026 earnings call. The Nov. 12 release did not give a date for that call. It also said a registrational study readout for its propionic acidemia treatment is expected in late 2026, and early results for a multiple myeloma therapy will be presented at the American Society of Hematology meeting in December 2026.
What It Means for You
A stock can fall on a day when the company raises its outlook. Investors often react to what comes next, not to what just happened.
Moderna is a reminder of how uneven profits can be in biotech. The third quarter brought net income, but the company lost money in each of the three quarters before it, and its 2026 cost of sales includes a $0.9 billion one-time litigation settlement charge.
The main risk here is spending. If the cancer vaccine does not win approval or sell as hoped, years of $4 billion-plus costs would weigh on the business. Prices after an event like this can keep moving in either direction.
| SPONSORED |
| |
|
It happened. Democrats flipped the House and took the Senate too.
Come January, they hold the purse strings. More spending means more printing — and the dollars you've saved buy less.
China is working to end the dollar's reign. Most of the world's oil is priced in U.S. dollars — that's what keeps America on top.
There is one asset no Congress can print into the ground and no foreign power can freeze.
The new Congress is sworn in January 3rd. The time to position is before then. Get all the details and claim your free Patriot Defense Guide right here.
|
|
|
Tidak ada komentar:
Posting Komentar